JMP Securities analyst David Turkaly reiterates an Outperform rating on iCAD with a $7 price target following recent updates from the company and the release of its Q3 results. Before the market open, iCAD announced that it entered into a strategic agreement with Google Health to enhance its portfolio of breast cancer artificial intelligence solutions, Turkaly tells investors in a research note. The analyst views the two main deal components "very favorably, particularly as it relates to technology-validation, first-mover advantages, and promoting enhanced diagnostic results to people around the globe ahead." He continues to believe the company’s offerings "provide best-in-class clinical and economic benefits and first-mover advantages."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ICAD:
- iCAD management to meet virtually with BTIG
- ICAD Rises on Cancer Imaging Deal with Google
- iCAD, Google Health enter development, commercialization agreement
- iCAD to Participate in the 13th Annual Craig-Hallum Alpha Select Conference
- iCAD to Join Forces with Radiology Partners, the Nation’s Largest Radiology Practice
